PRLD Prelude Therapeutics Incorporated

75.68
+1.13  (+2%)
Previous Close 74.55
Open 74.04
52 Week Low 23.6931
52 Week High 88.65
Market Cap $3,525,051,874
Shares 46,578,381
Float 44,585,270
Enterprise Value $3,237,626,303
Volume 261,181
Av. Daily Volume 215,686
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
PRT543
Solid tumors
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
PRT811
Solid Tumors and Recurrent High-Grade Gliomas
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or "the Company") (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share, which includes the exercise in full of the underwriters' option to purchase an additional 375,000 shares of its voting common stock. The aggregate gross proceeds from this offering were $172.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Prelude.

    Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities…

    WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or "the Company") (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share, which includes the exercise in full of the underwriters' option to purchase an additional 375,000 shares of its voting common stock. The aggregate gross proceeds from this offering were $172.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Prelude.

    Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities and Barclays acted as joint book-running managers for the offering.

    A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the "SEC") on January 6, 2021. The offering was made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649 or by email at ; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526 or by email at ; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001 Attn: Prospectus Department, or by email at ; or Barclays Capital Inc., c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Prelude Therapeutics

    Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company's lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude's first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). Prelude's diverse clinical pipeline also includes PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

    Forward Looking Statements

    This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include, but are not limited to, any statements regarding the development of Prelude's product candidates for certain indications. Such forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify, including risks resulting from COVID-19. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under "Risk Factors" in Prelude's periodic filings with the SEC, as well as the risks identified in the registration statement and prospectus relating to the offering. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the registration statement. Prelude undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    Contact

    Investors: Melissa Forst

    Media: Joshua Mansbach

    Argot Partners

    212.600.1902



    Primary Logo

    View Full Article Hide Full Article
  2. WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated ("Prelude" or "the Company") (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the pricing of its upsized public offering of 2,208,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share. The aggregate gross proceeds from this offering are expected to be $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Prelude. In addition, Prelude has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of voting common stock at…

    WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated ("Prelude" or "the Company") (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the pricing of its upsized public offering of 2,208,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share. The aggregate gross proceeds from this offering are expected to be $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Prelude. In addition, Prelude has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of voting common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 11, 2021, subject to the satisfaction of customary closing conditions.

    Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities and Barclays are acting as joint book-running managers for the offering.

    A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the "SEC") on January 6, 2021. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering, when available, may be obtained from Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649 or by email at ; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526 or by email at ; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001 Attn: Prospectus Department, or by email at ; or Barclays Capital Inc., c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Prelude Therapeutics

    Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company's lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude's first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). Prelude's diverse clinical pipeline also includes PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

    Forward Looking Statements

    This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include, but are not limited to, any statements regarding the development of Prelude's product candidates for certain indications, and statements regarding the completion and anticipated proceeds of the offering. Such forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify, including risks resulting from COVID-19. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under "Risk Factors" in Prelude's periodic filings with the SEC, as well as the risks identified in the registration statement and prospectus relating to the offering. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the registration statement. Prelude undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    Contact

    Investors: Melissa Forst

    Media: Joshua Mansbach

    Argot Partners

    212.600.1902



    Primary Logo

    View Full Article Hide Full Article
  3. WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or "the Company") (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced that it has commenced a public offering of 1,750,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission ("SEC"). All shares of common stock to be sold in the offering will be sold by Prelude. In addition, Prelude expects to grant the underwriters a 30-day option to purchase up to an additional 262,500 shares of common stock at the public offering price, less underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or…

    WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or "the Company") (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced that it has commenced a public offering of 1,750,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission ("SEC"). All shares of common stock to be sold in the offering will be sold by Prelude. In addition, Prelude expects to grant the underwriters a 30-day option to purchase up to an additional 262,500 shares of common stock at the public offering price, less underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities and Barclays are acting as joint book-running managers for the offering.

    A registration statement relating to these securities has been filed with the SEC and has not yet become effective. The proposed offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering, when available, may be obtained from Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649 or by email at ; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526 or by email at ; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001 Attn: Prospectus Department, or by email at ; or Barclays Capital Inc., c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at .

    These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Prelude Therapeutics

    Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company's lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude's first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). Prelude's diverse clinical pipeline also includes PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

    Forward Looking Statements

    This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include, but are not limited to, any statements regarding the development of Prelude's product candidates for certain indications, statements regarding the terms of the proposed public offering, including our expectations with respect to granting the underwriters a 30-day option to purchase additional shares, and the completion, timing and size of the proposed public offering. Such forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify, including risks resulting from COVID-19. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under "Risk Factors" in Prelude's periodic filings with the SEC, as well as the risks identified in the registration statement and preliminary prospectus relating to the offering. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the registration statement. Prelude undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    Contacts

    Investors: Melissa Forst

    Media: Joshua Mansbach

    Argot Partners

    212.600.1902



    Primary Logo

    View Full Article Hide Full Article
  4. - Completed Initial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M -

    - Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 Trial of PRT811 -

    - Durable Complete Response Ongoing in HRD+ High Grade Serous Ovarian Cancer Patient in Phase 1 Trial of PRT543 -

    WILMINGTON, Del., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude", "the Company", "we") (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced its financial results for the third quarter ended September 30, 2020 and provided an update on recent developments.

    "Prelude has evolved substantially to become a clinical-stage precision oncology company with multiple small molecule oral agents…

    - Completed Initial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M -

    - Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 Trial of PRT811 -

    - Durable Complete Response Ongoing in HRD+ High Grade Serous Ovarian Cancer Patient in Phase 1 Trial of PRT543 -

    WILMINGTON, Del., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude", "the Company", "we") (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced its financial results for the third quarter ended September 30, 2020 and provided an update on recent developments.

    "Prelude has evolved substantially to become a clinical-stage precision oncology company with multiple small molecule oral agents currently advancing through clinical trials," said Kris Vaddi, PhD, Chief Executive Officer, Prelude Therapeutics. "We continue to make great progress in advancing the clinical development of our lead PRMT5 inhibitors, PRT543 and PRT811, and believe we are well-positioned for continued success with the execution of these programs. We look forward to sharing additional data from each program in 2021."

    Dr. Vaddi added, "Beyond our PRMT5 program, we recently advanced our third product candidate, MCL1 inhibitor PRT1419, into the clinic for patients with hematologic malignancies, while our discovery engine continues to generate a diverse and robust pipeline. On the heels of our recent initial public offering resulting in gross proceeds of $181.9 million, we look forward to achieving additional clinical and regulatory milestones in the coming quarters."

    Clinical Program Highlights

    PRT543

    • Dose Expansion Portion of Phase 1 Trial to Commence by Year-End. The Company remains on track to commence the expansion portion of its Phase 1 trial of its lead product candidate, PRT543, which is designed to be a potent, selective, and oral inhibitor of PRMT5, in select solid tumor cohorts during the fourth quarter of 2020 and in select myeloid malignancy cohorts in early 2021. The expansion cohorts will include patients with adenoid cystic carcinoma (ACC), myelofibrosis (MF), genomically-selected myelodysplastic syndrome (MDS), and homologous recombination deficient positive (HRD+) tumors. Preliminary data from the dose escalation portion of the trial demonstrated early signs of clinical activity and tolerability, including a durable confirmed complete response (CR) in a patient with HRD+ high grade serous ovarian cancer who had received seven prior lines of therapy. The Company anticipates obtaining initial clinical data from these expansion cohorts in the first half of 2021 and presenting these data at medical meetings in 2021.

    PRT811

    • Dose Escalation Ongoing in Phase 1 Trial in Patients with Advanced Solid Tumors and Recurrent High-Grade Gliomas. The dose escalation portion of the Company's Phase 1 trial of its second clinical product candidate, PRT811, which is designed to be a potent, selective, and brain penetrant PRMT5 inhibitor, in patients with advanced solid tumors, including glioblastoma multiforme (GBM) and primary central nervous system lymphomas (PCNSL), remains ongoing. To date, the trial has demonstrated early signs of clinical activity and tolerability. The previously disclosed refractory GBM patient whose tumor had demonstrated a 66% reduction on monotherapy PRT811 has subsequently undergone a follow-up MRI at week 16 confirming a partial response (PR) per RANO (response assessment in neuro-oncology) criteria. The Company expects to commence the dose expansion portion of the trial in the first half of 2021, with data expected by the end of 2021.

    PRT1419

    • Dosed First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies. In September 2020, Prelude announced dosing of the first patient in its first-in-human Phase 1 open-label, multicenter, dose-escalation study of PRT1419 in patients with relapsed/refractory hematologic malignancies. PRT1419, the Company's third clinical candidate, is designed to be an orally available, potent, and selective MCL1 inhibitor.

    Corporate Update

    • Completed Initial Public Offering (IPO). In September 2020, Prelude closed its IPO of 9,573,750 shares of common stock, including the full exercise of the underwriters' option to purchase up to 1,248,750 additional shares of common stock, at a public offering price of $19.00 per share. Aggregate gross proceeds to Prelude were approximately $181.9 million, before deducting underwriting discounts and commissions and other offering expenses of $15.3 million.
    • Strengthened Board of Directors with Two New Appointments. In August 2020, the Company announced the appointment of Mardi C. Dier and Victor Sandor, M.D., both highly accomplished industry veterans, to its Board of Directors.

    Third Quarter 2020 Financial Results

    • Cash and cash equivalents: Cash and cash equivalents as of September 30, 2020 were $234.8 million.
    • Research and Development (R&D) Expenses: For the third quarter of 2020, R&D expenses increased by $9.8 million to $15.3 million compared to $5.5 million for the third quarter of 2019. The increase was mainly due to increased clinical research costs for the PRT543 and PRT811 clinical trials and increased costs associated with the initiation of the clinical trial for PRT1419, which began in the third quarter of 2020. Prelude also incurred an increase in chemistry, manufacturing, and other costs for those trials. 
    • General and Administrative (G&A) Expenses: For the third quarter of 2020, G&A expenses increased by $1.5 million to $2.9 million compared to $1.4 million for the third quarter of 2019. The increase was primarily due to an increase in personnel related expense due to increases in employee headcount and an increase in professional fees as Prelude expanded its operations to support its research and development efforts and incurred additional costs to operate as a public company.
    • Net Loss: For the third quarter of 2020, net loss was $16.8 million, or $5.25 per share, compared to a net loss of $6.7 million, or $3.93 per share, for the third quarter of 2019.

    About Prelude Therapeutics

    Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company's lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude's first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company's diverse clinical pipeline also includes PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities, timing of availability and announcements of clinical results, the timing of the expansion portion for its Phase 1 clinical trial for PRT543 and PRT811 and the potential benefits of the Company's product candidates and platform. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the impact of the COVID-19 pandemic on the Company's business, clinical trial sites, supply chain and manufacturing facilities, the Company's ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company's ability to fund development activities and achieve development goals, the Company's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.





    Statements of Operations

    (unaudited)

      Three Months Ended September 30, 
    (in thousands, except share and per share data) 2020  2019 
    Operating expenses:        
    Research and development $15,293  $5,490 
    General and administrative  2,851   1,394 
    Total operating expenses  18,144   6,884 
    Loss from operations  (18,144)  (6,884)
    Other income, net  1,384   150 
    Net loss $(16,760) $(6,734)
    Per share information:        
    Net loss per share of common stock, basic and diluted $(5.25) $(3.93)
    Weighted average common shares outstanding, basic and diluted  3,194,471   1,713,371 





    Balance Sheets

    (unaudited)

    (in thousands, except share data) September 30,

    2020
       December 31,

    2019
     
    Assets       
    Current assets:       
    Cash and cash equivalents$234,792  $18,879 
    Prepaid expenses and other current assets 3,269   1,345 
    Total current assets 238,061   20,224 
    Property and equipment, net 1,620   1,647 
    Total assets$239,681  $21,871 
    Liabilities, convertible preferred stock and stockholders' equity (deficit)       
    Current liabilities:       
    Capital lease obligation$  $258 
    Accounts payable 5,074   1,974 
    Accrued expenses and other current liabilities 6,285   2,603 
    Total current liabilities 11,359   4,835 
    Other liabilities 15   5 
    Total liabilities 11,374   4,840 
    Convertible preferred stock, $0.0001 par value:       
    Series A convertible preferred stock: No shares and 13,574,008 shares

    authorized at September 30, 2020 and December 31, 2019, respectively; no shares and 11,736,119 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively
        36,595 
    Series B convertible preferred stock: No shares and 18,500,000 shares

    authorized at September 30, 2020 and December 31, 2019; No shares and 7,628,846 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively
        29,848 
    Series C convertible preferred stock: no shares authorized, issued or outstanding at September 30, 2020 and December 31, 2019     
    Total convertible preferred stock    66,443 
    Stockholders' equity (deficit):       
    Voting common stock, $0.0001 par value: 487,149,741 and 42,000,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 32,593,010 and 3,161,653 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively 3    
    Non-voting common stock, $0.0001 par value; 12,850,259 and no shares

    authorized at September 30, 2020 and December 31, 2019, respectively; 11,110,371 and no shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively
     1    
    Additional paid-in capital 316,479   1,085 
    Accumulated deficit (88,176)  (50,497)
    Total stockholders' equity (deficit) 228,307   (49,412)
    Total liabilities, convertible preferred stock and stockholders' equity (deficit)$239,681  $21,871 



    Contact

    Investors: Melissa Forst

    Media: Joshua Mansbach

    Argot Partners

    212.600.1902

    Primary Logo

    View Full Article Hide Full Article
View All Prelude Therapeutics Incorporated News